Vaccinex (VCNX) AI Stock Analysis

• Market Cap: $1.81M
• Dividend Yield: N/A
• Average Volume (3M): 4.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.38
• Revenue Growth: -51.19%
• EPS Growth: 85.01%
• Country: US
• Employees: 37
• Sector: Healthcare
• Sector Strength: 69
• Industry: Biotechnology
• EPS (TTM): -12.58
• Shares Outstanding: 2,599,728
• 10 Day Avg. Volume: 2,275
• 30 Day Avg. Volume: 4,422
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 3.82
• Price to Cash Flow (P/CF): -0.10
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Vaccinex's stock is heavily impacted by its poor financial performance, characterized by negative profitability and cash flow. Technical analysis indicates a bearish trend with high volatility. Valuation metrics are unfavorable due to negative earnings and no dividend yield. The neutral stance from the earnings call does not provide a catalyst for significant change.

Vaccinex Business Overview & Revenue Model

Company Description

Vaccinex, Inc. (VCNX) is a clinical-stage biotechnology company specializing in the development of targeted biotherapeutics to treat cancer and neurodegenerative diseases. The company's proprietary technology platforms include the ActivMAb antibody discovery and novel drug development platform and the SEMA4D pathway inhibitor platform. Vaccinex's lead product candidates are focused on addressing significant unmet medical needs in oncology and neurology.

How the Company Makes Money

Vaccinex primarily generates revenue through strategic collaborations and licensing agreements with pharmaceutical and biotechnology companies. These partnerships often involve milestone payments and royalties, providing a financial return as Vaccinex advances its drug candidates through various stages of development. Additionally, the company may receive funding from grants and research support from government and non-profit organizations to advance its scientific research. Vaccinex aims to bring its proprietary therapies to market, which would potentially provide significant revenue through product sales. However, as a clinical-stage company, substantial revenue from direct product sales is contingent upon successful clinical trials and regulatory approval.

Vaccinex Financial Statement Overview

Summary

Vaccinex is facing significant financial challenges across all fronts. The income statement reveals consistent losses, the balance sheet shows financial instability with negative equity, and cash flows are predominantly negative. The company needs to address these issues to improve its financial health and stability.

Income Statement

The company exhibits a continuous decline in profitability, with a negative gross profit margin and net profit margin. Revenue growth is erratic, with significant fluctuations over the years. EBIT and EBITDA margins are deeply negative, indicating operational challenges in achieving profitability.

Balance Sheet

The balance sheet shows negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is not meaningful due to negative equity, but the company has a relatively low level of total debt. The equity ratio is negative, reflecting a severe financial risk profile.

Cash Flow

Cash flow from operations is consistently negative, indicating a struggle to generate cash from core operations. Free cash flow is also negative, although there is a noticeable reduction in the negative free cash flow trend over the recent period, suggesting a slight improvement.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
2.00K	570.00K	100.00K	900.00K	50.00K	523.00K
	Gross Profit
-3.92M	570.00K	-107.00K	731.00K	48.00K	324.00K
	EBIT
-20.34M	-22.89M	-19.91M	-22.49M	-28.33M	-32.02M
	EBITDA
-18.55M	-19.75M	-19.61M	-21.40M	-28.05M	-31.61M
	Net Income Common Stockholders
-18.58M	-20.25M	-19.72M	-23.23M	-29.31M	-32.02M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.66M	1.53M	6.39M	8.59M	10.60M	2.78M
	Total Assets
0.00	3.63M	7.98M	9.84M	11.70M	4.60M
	Total Debt
0.00	247.00K	485.00K	390.00K	9.21M	0.00
	Net Debt
1.66M	-1.29M	-5.91M	-8.20M	-1.39M	-2.78M
	Total Liabilities
0.00	5.94M	2.78M	2.43M	14.31M	6.88M
	Stockholders Equity
-3.33M	-2.31M	5.19M	7.41M	-26.57M	-26.24M
Cash Flow		Free Cash Flow
-15.87M	-17.30M	-19.17M	-25.33M	-28.94M	-30.79M
	Operating Cash Flow
-15.85M	-17.23M	-19.07M	-25.30M	-28.65M	-30.71M
	Investing Cash Flow
-22.00K	-67.00K	-99.00K	-32.00K	-290.00K	14.07M
	Financing Cash Flow
18.65M	12.45M	16.98M	23.32M	36.76M	13.80M

Vaccinex Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VCNX, the sentiment is Negative. The current price of 0.7 is above the 20-day moving average (MA) of 0.68, below the 50-day MA of 0.89, and below the 200-day MA of 3.15, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 47.01 is Neutral, neither overbought nor oversold. The STOCH value of 60.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VCNX.

Vaccinex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BNTX	54 Neutral	$22.35B	―	-3.38%	―	-27.64%	-172.62%
VXRT	49 Neutral	$81.29M	―	-114.71%	―	288.94%	39.45%
MRNA	48 Neutral	$9.45B	―	-28.77%	―	-52.75%	25.00%
Sector *	48 Neutral	$6.35B	1.19	-46.26%	2.67%	19.24%	1.75%
INBX	42 Neutral	$163.87M	0.10	919.96%	―	―	―
NVAX	34 Underperform	$873.38M	―	30.06%	―	-30.65%	77.62%
VCNX	33 Underperform	$1.81M	―	1406.28%	―	-51.19%	85.01%